Literature DB >> 7248945

Differential effect of chronic ethanol consumption on the carcinogenicity of N-nitrosopyrrolidine and N'-nitrosonornicotine in male Syrian golden hamsters.

G D McCoy, S S Hecht, S Katayama, E L Wynder.   

Abstract

The effect of chronic ethanol consumption on the carcinogenicity of N'-nitrosopyrrolidine (NPYR) and N'-nitrosonornicotine (NNN) in male Syrian golden hamsters has been investigated. Groups of hamsters were maintained on either ethanol-containing or control liquid diets for 4 weeks prior to and during carcinogen treatment. NPYR or NNN was administered to ethanol-consuming or control hamsters by i.p. injection over a 25-week period in total doses of either 1 or 2 mmol. In the group treated with 1 mmol of NPYR and maintained on a control diet, we observed 1 of 20 hamsters with a nasal cavity tumor and 4 of 20 hamsters with tracheal tumors. In the group treated with 1 mmol of NPYR and maintained on the ethanol-containing diet, we observed 8 of 18 hamsters with nasal cavity tumors and 9 of 18 hamsters with tracheal tumors. The corresponding results in hamsters given 2 mmol of NPYR were: nasal cavity tumors, 14 of 21 (control) and 16 of 17 (ethanol); tracheal tumors, 8 of 21 (control) and 11 of 17 (ethanol). These results demonstrate that the carcinogenicity of NPYR is enhanced in ethanol-treated Syrian golden hamsters, particularly at the lower dose. In the groups treated with 1 mmol of NN and a control diet, we observed 1 of 21 hamsters with a nasal cavity tumor and 4 of 21 with tracheal tumors. In the corresponding ethanol-treated groups, we observed 1 of 17 hamsters with a nasal tumor and 5 of 17 with tracheal tumors. In the hamsters given 2 mmol of NNN, the results were: nasal cavity tumors, 5 of 21 (control) and 4 of 21 (ethanol); tracheal tumors, 9 of 21 (control) and 7 of 21 (ethanol). Thus, the carcinogenicity of NNN in the Syrian golden hamster was not affected by ethanol treatment. These results suggest that the metabolic activation of NPYR, but not that of NNN, may be enhanced by chronic ethanol consumption in the Syrian golden hamster.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248945

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Covalent binding of aflatoxin B1 to liver DNA in rats pretreated with ethanol.

Authors:  M Marinovich; W K Lutz
Journal:  Experientia       Date:  1985-10-15

2.  Metabolism of ethanol and carcinogens by glutathione transferases.

Authors:  P S Bora; C A Spilburg; L G Lange
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

3.  Identification of a satellite fatty acid ethyl ester synthase from human myocardium as a glutathione S-transferase.

Authors:  P S Bora; C A Spilburg; L G Lange
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 4.  Metabolic Activation and DNA Interactions of Carcinogenic N-Nitrosamines to Which Humans Are Commonly Exposed.

Authors:  Yupeng Li; Stephen S Hecht
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

Review 5.  Hepatocellular carcinoma, alcohol, and cirrhosis: facts and hypotheses.

Authors:  R Naccarato; F Farinati
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

Review 6.  [Alcohol related diseases of the head and neck].

Authors:  F Riedel; K Hörmann
Journal:  HNO       Date:  2004-07       Impact factor: 1.284

Review 7.  Roles of Cytochrome P450 in Metabolism of Ethanol and Carcinogens.

Authors:  F Peter Guengerich; Narayan G Avadhani
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  Enhancing effect of ethanol on aflatoxin B1-induced hepatocarcinogenesis in male ACI/N rats.

Authors:  T Tanaka; A Nishikawa; H Iwata; Y Mori; A Hara; I Hirono; H Mori
Journal:  Jpn J Cancer Res       Date:  1989-06

9.  Tumor enhancers: underestimated factors in the epidemiology of lifestyle-associated cancers.

Authors:  E L Wynder
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.